Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

New AI Tool Reveals Single-Cell Structure of Chromosomes -- In 3D May 28, 2025 — In a major leap forward for genetic and biomedical research, scientists have developed a powerful new artificial ...